2024 surveillance of bladder cancer: diagnosis and management (NICE guideline NG2)
Prioritisation board agreed there is new evidence in this area which has the potential to impact on the existing recommendations.
Review decision: Prioritised
We have checked the evidence and plan to update recommendations on treating non-muscle invasive bladder cancer, treating muscle-invasive bladder cancer and managing locally advanced or metastatic muscle-invasive bladder cancer.
This page was last updated: